Sherry Aulin - Xenon Pharmaceuticals Chief Officer
| XENE Stock | USD 38.52 1.10 2.78% |
Insider
Sherry Aulin is Chief Officer of Xenon Pharmaceuticals
| Age | 40 |
| Address | 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 |
| Phone | 604 484 3300 |
| Web | https://www.xenon-pharma.com |
Latest Insider Transactions
Sherry Aulin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sherry Aulin against Xenon Pharmaceuticals stock is an integral part of due diligence when investing in Xenon Pharmaceuticals. Sherry Aulin insider activity provides valuable insight into whether Xenon Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Xenon Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Xenon Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sherry Aulin over a month ago Disposition of 9334 shares by Sherry Aulin of Xenon Pharmaceuticals at 9.44 subject to Rule 16b-3 |
Xenon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1892) % which means that it has lost $0.1892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2671) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals' management efficiency ratios could be used to measure how well Xenon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 19, 2025, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Xenon Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 8.9 M, whereas Return On Tangible Assets are forecasted to decline to (0.23).Similar Executives
| Showing other executives | INSIDER Age | ||
| Prof MD | Lyell Immunopharma | N/A | |
| Karen Alderete | Vaxcyte | N/A | |
| Sushil Patel | Replimune Group | 54 | |
| JD MBA | United Therapeutics | 67 | |
| Jeff Fairman | Vaxcyte | 61 | |
| BCh BM | Kronos Bio | 40 | |
| James Spudich | Cytokinetics | 83 | |
| Susanna MBA | Dyne Therapeutics | 56 | |
| Crystal MD | Lyell Immunopharma | 64 | |
| Marni Kottle | Kronos Bio | N/A | |
| Michael MBA | Arcellx | N/A | |
| Jillian Connell | Merus BV | N/A | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Gary Lee | Lyell Immunopharma | 48 | |
| Mark Lappe | Inhibrx | 58 | |
| Stephen Hill | Lyell Immunopharma | 55 | |
| Robert MD | MeiraGTx Holdings PLC | 62 | |
| MS MD | Dyne Therapeutics | 57 | |
| Tanya MS | Replimune Group | 53 | |
| Darlene Noci | Nuvalent | 47 | |
| Jeffrey Hager | Ideaya Biosciences | 59 | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 |
Xenon Pharmaceuticals Leadership Team
Elected by the shareholders, the Xenon Pharmaceuticals' board of directors comprises two types of representatives: Xenon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenon. The board's role is to monitor Xenon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xenon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CMA CPA, CEO Pres | ||
| MBA MPH, Chief Officer | ||
| Sherry Aulin, Chief Officer | ||
| Christopher MD, Chief Officer | ||
| Andrea JD, Chief Secretary | ||
| Robin Sherrington, Sr. VP of Bus. and Corporate Devel. | ||
| MBA MSc, Ex Operations | ||
| Shelley BA, Executive Resources | ||
| James Empfield, Senior Vice President - Drug Discovery |
Xenon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.29 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 3.48 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 3.68 X | ||||
| Price To Sales | 181.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.